Cynapsus confirms Parkinson’s treatment in drug trial

Cynapsus Therapeutics (TSX-V:CTH) has released positive top-line data from a human volunteer proof-of-concept trial for APL-130277, a sublingual thin film strip formulation of apomorphine, for the treatment of motor fluctuations or “off episodes” in Parkinson’s disease. The study showed a pharmacokinetic profile that compares favorably to injected apomorphine, with a mean T-max, or the time [...]

Parkinson’s-causing gene discovered at UBC

Research by scientists at the University of British Columbia, which identified a genetic mutation that causes late-onset Parkinson’s disease, has been published in the peer-reviewed American Journal of Human Genetics. The mutation, known as VPS35, was isolated using DNA taken from a Swiss family in which 11 people have developed the disease. Carles Vilarino-Guell, a [...]

Cynapsus posts positive proof-of-concept results

Cynapsus Therapeutics (TSX-V:CTH) has obtained positive results in proof-of-concept studies comparing prototypes of its APL-130277 treatment for Parkinson’s disease with injectable apomorphine. “The achievement of this important milestone is crucial, as we believe these results have significantly de-risked the project, from the perspective of a sublingual thin film-strip delivering drug to the blood stream in [...]

Cynapsus sets testing of Parkinson’s drug

Cynapsus Therapeutics (TSX-V:CTH) plans to begin proof-of-concept studies comparing preliminary prototypes of APL-130277, its potential treatment for Parkinson’s disease, with injectable apomorphine near the end of the year. “This is an important milestone that is necessary before commencing human clinical studies in early 2011,” CEO Anthony Giovinazzo said in a statement. Among other developments, Cynapsus [...]

Cannasat in LOI for Parkinson’s drug

Cannasat Therapeutics (TSX-V:CTH) has entered into a letter of intent with Adagio Pharmaceuticals, granting Cannasat the option to license all intellectual property relating to APL-130277, a reformulation of an approved drug for Parkinson’s disease. The accord would result in Cannasat assuming product development and commercialization rights to APL-130277 from Adagio in return for development milestones and [...]